These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
279 related items for PubMed ID: 28138513
1. KDM5 lysine demethylases are involved in maintenance of 3'UTR length. Blair LP, Liu Z, Labitigan RL, Wu L, Zheng D, Xia Z, Pearson EL, Nazeer FI, Cao J, Lang SM, Rines RJ, Mackintosh SG, Moore CL, Li W, Tian B, Tackett AJ, Yan Q. Sci Adv; 2016 Nov; 2(11):e1501662. PubMed ID: 28138513 [Abstract] [Full Text] [Related]
5. KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Hinohara K, Wu HJ, Vigneau S, McDonald TO, Igarashi KJ, Yamamoto KN, Madsen T, Fassl A, Egri SB, Papanastasiou M, Ding L, Peluffo G, Cohen O, Kales SC, Lal-Nag M, Rai G, Maloney DJ, Jadhav A, Simeonov A, Wagle N, Brown M, Meissner A, Sicinski P, Jaffe JD, Jeselsohn R, Gimelbrant AA, Michor F, Polyak K. Cancer Cell; 2018 Dec 10; 34(6):939-953.e9. PubMed ID: 30472020 [Abstract] [Full Text] [Related]
6. Histone lysine demethylase KDM5B maintains chronic myeloid leukemia via multiple epigenetic actions. Xue S, Lam YM, He Z, Zheng Y, Li L, Zhang Y, Li C, Mbadhi MN, Zheng L, Cheng Z, Liu Y, Wang X, Chan LC, Ng RK, Zhang J. Exp Hematol; 2020 Feb 10; 82():53-65. PubMed ID: 32007477 [Abstract] [Full Text] [Related]
10. KDM5A and KDM5B histone-demethylases contribute to HU-induced replication stress response and tolerance. Gaillard S, Charasson V, Ribeyre C, Salifou K, Pillaire MJ, Hoffmann JS, Constantinou A, Trouche D, Vandromme M. Biol Open; 2021 May 15; 10(5):. PubMed ID: 34184733 [Abstract] [Full Text] [Related]
11. SUMOylation negatively modulates target gene occupancy of the KDM5B, a histone lysine demethylase. Bueno MT, Richard S. Epigenetics; 2013 Nov 15; 8(11):1162-75. PubMed ID: 23970103 [Abstract] [Full Text] [Related]
12. Structure-based design and discovery of potent and selective KDM5 inhibitors. Nie Z, Shi L, Lai C, O'Connell SM, Xu J, Stansfield RK, Hosfield DJ, Veal JM, Stafford JA. Bioorg Med Chem Lett; 2018 May 15; 28(9):1490-1494. PubMed ID: 29627262 [Abstract] [Full Text] [Related]
13. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor. Kristensen LH, Nielsen AL, Helgstrand C, Lees M, Cloos P, Kastrup JS, Helin K, Olsen L, Gajhede M. FEBS J; 2012 Jun 15; 279(11):1905-14. PubMed ID: 22420752 [Abstract] [Full Text] [Related]
14. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448. Bamodu OA, Huang WC, Lee WH, Wu A, Wang LS, Hsiao M, Yeh CT, Chao TY. BMC Cancer; 2016 Feb 25; 16():160. PubMed ID: 26917489 [Abstract] [Full Text] [Related]
15. Structure of the Arabidopsis JMJ14-H3K4me3 Complex Provides Insight into the Substrate Specificity of KDM5 Subfamily Histone Demethylases. Yang Z, Qiu Q, Chen W, Jia B, Chen X, Hu H, He K, Deng X, Li S, Tao WA, Cao X, Du J. Plant Cell; 2018 Jan 25; 30(1):167-177. PubMed ID: 29233856 [Abstract] [Full Text] [Related]
18. Histone demethylase lysine demethylase 5B in development and cancer. Han M, Xu W, Cheng P, Jin H, Wang X. Oncotarget; 2017 Jan 31; 8(5):8980-8991. PubMed ID: 27974677 [Abstract] [Full Text] [Related]